View Item 

Show simple item record

A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam
dc.contributor.authorSnyder, Peter J.en_US
dc.contributor.authorFeltner, Douglas E.en_US
dc.contributor.authorCaveney, Angela F.en_US
dc.contributor.authorGiordani, Brunoen_US
dc.contributor.authorMaruff, Paulen_US
dc.contributor.authorWerth, Johnen_US
dc.date.accessioned2006-09-11T17:42:23Z
dc.date.available2006-09-11T17:42:23Z
dc.date.issued2006-05en_US
dc.identifier.citationMaruff, Paul; Werth, John; Giordani, Bruno; Caveney, Angela F.; Feltner, Douglas; Snyder, Peter J.; (2006). "A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam." Psychopharmacology 186(1): 7-17. <http://hdl.handle.net/2027.42/46374>en_US
dc.identifier.issn1432-2072en_US
dc.identifier.issn0033-3158en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46374
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16572266&dopt=citationen_US
dc.description.abstractThe effects of any drug treatment on cognitive function are typically studied in groups of subjects. Observations made about the behavior of the drug, in the study sample, are then generalized to the population from which the sample was drawn. However, the magnitude and pharmacodynamic qualities of the response to many central nervous system-active drugs are known to vary in the population. Therefore, it is useful to consider statistical models for the detection of cognitive change in response to a drug treatment in individual subjects.en_US
dc.format.extent174973 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.titleA statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolamen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumSection of Neuropsychology, Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationumSection of Neuropsychology, Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationotherDepartment of Psychology, University of Connecticut (Storrs, CT) & CNS Early Development, Pfizer Global Research & Development, Groton, CT, USA,en_US
dc.contributor.affiliationotherCogState Ltd, Melbourne, Australia,en_US
dc.contributor.affiliationotherCNS Early Development, Pfizer Global Research & Development, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationotherCNS Early Development, Pfizer Global Research & Development, Ann Arbor, MI, USA,en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid16572266en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46374/1/213_2006_Article_331.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/s00213-006-0331-5en_US
dc.identifier.sourcePsychopharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
213_2006_Article_331.pdf
Size:
170.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.